Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

May 31, 2009

Conditions
Choroidal Neovascularization
Interventions
DRUG

Ranibizumab

0.3 mg/0.05 ml dose

DRUG

Ranibizumab

0.5 mg/0.05 ml dose

Trial Locations (1)

21287

The Wilmer Eye Institute at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER